The purpose of this study is to determine the side effects and antitumor response of patients with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin.

Deoxycoformycin(DCF)/Pentostatin is a T-cell cytotoxic drug with previously reported responses in lymphoid malignancies but larger studies are needed.

Inclusion Criteria:

• Histologic proof of lymphoid malignancy with an expected complete response rate of less than 20 percent OR have failed at least one prior therapy.
• No chemotherapy within 3 weeks of entry into study and must have recovered from acute toxic effects of prior therapy.
• Life expectancy of at least 12 weeks.
• Performance status equal to or less than Zubrod 2.
• Signed informed consent.
• Patients with measurable disease.
• Age at least 16 years.
• Adequate bone marrow function (unless involvement of bone marrow by lymphoma) defined as AGC greater than 1500 and platelet count greater than 100,000.
• Adequate hepatic function with a bilirubin less than or equal to 1.5 mg % and SGPT less than or equal to 4 times the upper limits of normal.
• Adequate renal function defined as serum creatine less than or equal to 1.5 mg %.

Exclusion Criteria:

• No serious intercurrent illness.
• Adequate contraception (if applicable).
• NO patients with significant cardiac disease, i.e. New York Heart Association (NYHA) class III or IV.
• NO experimental clinical trial within 3 weeks of study entry.
• NO patients with active CNS disease.
• Full recovery from any prior surgical treatment.
• NO active active infections.